APO RESEARCH · REPORT
Myotonic Dystrophy Drug
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Product & engineering
Understand the product.
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.
Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
Selected research
Industry Research
Myotonic Dystrophy Drug Industry Research Report 2026
Market perspective
Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.
Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
Read the full market overview
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.
Report Scope
This report quantifies the global Myotonic Dystrophy Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Myotonic Dystrophy Drug Market by Company
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt
Myotonic Dystrophy Drug Segment by Type
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Myotonic Dystrophy Drug Segment by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Other
Myotonic Dystrophy Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myotonic Dystrophy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Myotonic Dystrophy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myotonic Dystrophy Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Myotonic Dystrophy Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Myotonic Dystrophy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sodium Channel Blocker
- Tricyclic Antidepressant
- Other
Applications
- Hospital Pharmacy
- Retail Pharmacy
- Other
Companies covered
- Lupin
- Teva
- ANI Pharmaceuticals
- Mylan
- Novartis
- Sun Pharma
- Mallinckrodt
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Myotonic Dystrophy Drug Market Size (2021-2032)
- 2.2.2 Global Myotonic Dystrophy Drug Sales (2021-2032)
- 2.2.3 Global Myotonic Dystrophy Drug Market Average Price (2021-2032)
- 2.3 Myotonic Dystrophy Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Sodium Channel Blocker
- 2.3.3 Tricyclic Antidepressant
- 2.3.4 Other
- 2.4 Myotonic Dystrophy Drug by Distribution Channel
- 2.4.1 Market Value Comparison by Distribution Channel (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacy
- 2.4.3 Retail Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Myotonic Dystrophy Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Myotonic Dystrophy Drug Sales (K Unit) of Manufacturers (2021-2026)
- 3.3 Global Myotonic Dystrophy Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Myotonic Dystrophy Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Myotonic Dystrophy Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Myotonic Dystrophy Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Myotonic Dystrophy Drug, Product Type & Application
- 3.8 Global Manufacturers of Myotonic Dystrophy Drug, Established Date
- 3.9 Global Myotonic Dystrophy Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Lupin
- 4.1.1 Lupin Company Information
- 4.1.2 Lupin Business Overview
- 4.1.3 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio
- 4.1.5 Lupin Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Myotonic Dystrophy Drug Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 ANI Pharmaceuticals
- 4.3.1 ANI Pharmaceuticals Company Information
- 4.3.2 ANI Pharmaceuticals Business Overview
- 4.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio
- 4.3.5 ANI Pharmaceuticals Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Sun Pharma
- 4.6.1 Sun Pharma Company Information
- 4.6.2 Sun Pharma Business Overview
- 4.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio
- 4.6.5 Sun Pharma Recent Developments
- 4.7 Mallinckrodt
- 4.7.1 Mallinckrodt Company Information
- 4.7.2 Mallinckrodt Business Overview
- 4.7.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio
- 4.7.5 Mallinckrodt Recent Developments
5 Global Myotonic Dystrophy Drug Market Scenario by Region
- 5.1 Global Myotonic Dystrophy Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Myotonic Dystrophy Drug Sales by Region: 2021-2032
- 5.2.1 Global Myotonic Dystrophy Drug Sales by Region: 2021-2026
- 5.2.2 Global Myotonic Dystrophy Drug Sales by Region: 2027-2032
- 5.3 Global Myotonic Dystrophy Drug Revenue by Region: 2021-2032
- 5.3.1 Global Myotonic Dystrophy Drug Revenue by Region: 2021-2026
- 5.3.2 Global Myotonic Dystrophy Drug Revenue by Region: 2027-2032
- 5.4 North America Myotonic Dystrophy Drug Market Facts & Figures by Country
- 5.4.1 North America Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Myotonic Dystrophy Drug Sales by Country (2021-2032)
- 5.4.3 North America Myotonic Dystrophy Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Myotonic Dystrophy Drug Market Facts & Figures by Country
- 5.5.1 Europe Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Myotonic Dystrophy Drug Sales by Country (2021-2032)
- 5.5.3 Europe Myotonic Dystrophy Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Myotonic Dystrophy Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Myotonic Dystrophy Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Myotonic Dystrophy Drug Market Facts & Figures by Country
- 5.7.1 South America Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Myotonic Dystrophy Drug Sales by Country (2021-2032)
- 5.7.3 South America Myotonic Dystrophy Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Myotonic Dystrophy Drug Sales by Type (2021-2032)
- 6.1.1 Global Myotonic Dystrophy Drug Sales by Type (2021-2032) & (K Unit)
- 6.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Myotonic Dystrophy Drug Revenue by Type (2021-2032)
- 6.2.1 Global Myotonic Dystrophy Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Myotonic Dystrophy Drug Price by Type (2021-2032)
7 Segment by Distribution Channel
- 7.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2032)
- 7.1.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2032) & (K Unit)
- 7.1.2 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2021-2032)
- 7.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2021-2032)
- 7.2.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2032) & (US$ Million)
- 7.2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2021-2032)
- 7.3 Global Myotonic Dystrophy Drug Price by Distribution Channel (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Myotonic Dystrophy Drug Value Chain Analysis
- 8.1.1 Myotonic Dystrophy Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Myotonic Dystrophy Drug Production Mode & Process
- 8.2 Myotonic Dystrophy Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Myotonic Dystrophy Drug Distributors
- 8.2.3 Myotonic Dystrophy Drug Customers
9 Global Myotonic Dystrophy Drug Analyzing Market Dynamics
- 9.1 Myotonic Dystrophy Drug Industry Trends
- 9.2 Myotonic Dystrophy Drug Industry Drivers
- 9.3 Myotonic Dystrophy Drug Industry Opportunities and Challenges
- 9.4 Myotonic Dystrophy Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst